We are live on ! Find out more
FGP

Foyston, Gordon, & Payne Portfolio holdings

AUM $434M
1-Year Est. Return 9.09%
This Fund
S&P 500
This Quarter Est. Return
+2.79%
1 Year Est. Return
+9.09%
3 Year Est. Return
+56.86%
5 Year Est. Return
+84.63%
10 Year Est. Return
+238.52%
AUM
$378M
AUM Growth
-$23.3M
Cap. Flow
-$28M
Cap. Flow %
-7.41%
Top 10 Hldgs %
51.76%
Holding
55
New
2
Increased
11
Reduced
25
Closed
3

Top Buys

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$2.59M
2
LRCX icon
Lam Research
LRCX
+$2.5M
3
HL icon
Hecla Mining
HL
+$284K
4
G icon
Genpact
G
+$155K
5
AOS icon
A.O. Smith
AOS
+$58.2K

Top Sells

Rank Stock Value
1
GNTX icon
Gentex
GNTX
+$4.92M
2
TFC icon
Truist Financial
TFC
+$4.75M
3
UNH icon
UnitedHealth
UNH
+$3.46M
4
WTW icon
Willis Towers Watson
WTW
+$3.16M
5
ULTA icon
Ulta Beauty
ULTA
+$3.07M

Sector Composition

Rank Sector Weight
1 Technology 31.17%
2 Healthcare 14.32%
3 Financials 14.08%
4 Consumer Staples 11.19%
5 Consumer Discretionary 10.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NSP icon
51
Insperity
NSP
$1.93B
$230K 0.06%
2,973
SKX
52
DELISTED
Skechers
SKX
$208K 0.06%
3,100
GNTX icon
53
Gentex
GNTX
$4.97B
-165,835
Closed -$4.92M
TFC icon
54
Truist Financial
TFC
$63.3B
-111,030
Closed -$4.75M
ULTA icon
55
Ulta Beauty
ULTA
$22B
-7,882
Closed -$3.07M

Similar funds

Foyston, Gordon, & Payne's Q4 2024 Portfolio in Review

As of Q4 2024, Foyston, Gordon, & Payne held 55 positions worth $378M, down 5.8% from $401M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Foyston, Gordon, & Payne withdrew a net $28M in Q4 2024, closing 3 positions and reducing 25 holdings. Its most notable exit was Gentex, an estimated $4.92M position sold in full.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Foyston, Gordon, & Payne opened a new position in Lam Research worth $2.38M.

  • Foyston, Gordon, & Payne's largest Q4 2024 buy was Lam Research: 32,971 shares worth $2.38M.
  • Foyston, Gordon, & Payne added most to Icon in Q4 2024, an estimated $2.59M increase.
  • Foyston, Gordon, & Payne's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $3.46M.
  • Foyston, Gordon, & Payne fully exited Gentex in Q4 2024, selling an estimated $4.92M.
  • Foyston, Gordon, & Payne's ten largest holdings make up 52% of its $378M portfolio in Q4 2024.
  • Foyston, Gordon, & Payne opened 2 new positions and closed 3 in Q4 2024.
  • Foyston, Gordon, & Payne's portfolio value fell 5.8% quarter-over-quarter to $378M.

Based on Foyston, Gordon, & Payne's 13F filing for Q4 2024, filed 14 Feb 2025.